Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.7764
+0.0190 (2.51%)
At close: Oct 28, 2026, 4:00 PM EDT
0.7801
+0.0037 (0.48%)
Pre-market: Oct 29, 2026, 5:59 AM EDT
Ocugen Revenue
Ocugen had revenue of $1.49M in the quarter ending June 30, 2026, with 8.38% growth. In the year 2025, Ocugen had annual revenue of $4.41M with 8.83% growth. That makes Ocugen the 40,246th largest company in the world by revenue and 5,355th in the United States.
Revenue (ttm)
$4.41M
Revenue Growth
+8.83%
P/S Ratio
57.47
Revenue / Employee
$39,491
Employees
116
Market Cap
263.29M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.41M | 358.00K | 8.83% |
| Dec 31, 2024 | 4.06M | -1.98M | -32.82% |
| Dec 31, 2023 | 6.04M | 3.55M | 142.60% |
| Dec 31, 2022 | 2.49M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 43.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 8.00K | -18.00K | -69.23% |
| Dec 31, 2012 | 26.00K | -97.00K | -78.86% |
| Dec 31, 2011 | 123.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Clinuvel Pharmaceuticals | 65.05M |
| Bicycle Therapeutics | 61.21M |
| Q32 Bio | 53.74M |
| Abeona Therapeutics | 25.52M |
| Lineage Cell Therapeutics | 13.08M |
| Fate Therapeutics | 6.49M |
| SAB Biotherapeutics | 114.70K |
OCGN News
- 6 days ago - Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4 - GlobeNewsWire
- 14 days ago - Ocugen executes licensing agreement with Roots Pharmaceutical - TheFly
- 14 days ago - Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa - GlobeNewsWire
- 20 days ago - Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 21 days ago - Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update - Newsfile Corp
- 22 days ago - Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate - GlobeNewsWire
- 23 days ago - Ocugen Transcript: EGM 2026 - Transcripts
- 4 weeks ago - Ocugen to Participate in Upcoming Scientific Conferences - GlobeNewsWire